Pfizer Inc. Press Releases https://investors.pfizer.com/generated by Q4Fri, 12 Jun 2026 19:07:54 -0400Copyright Q4 Inc. All rights reserved.U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need3ee46cb7-8b33-4eec-8f0d-24228c183568https://investors.pfizer.com/Investors/news-events/News/news-details/2026/U-S--FDA-Approves-Pfizers-HYMPAVZI-for-the-Treatment-of-Two-Additional-Hemophilia-A-or-B-Patient-Populations-with-Significant-Medical-Need/default.aspxMon, 08 Jun 2026 06:45:00 -0400Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatideb34139a9-2761-471e-b4ed-856546c5020ehttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide/default.aspxSat, 06 Jun 2026 09:00:00 -0400Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference90f19d6b-0f02-43f5-a327-74008e130f68https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference-d15093844/default.aspxMon, 01 Jun 2026 10:00:00 -0400Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer6e845713-00ae-4002-aee9-2fb815b7f6c1https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizers-BRAFTOVI-Regimen-Nearly-Doubles-Median-Progression-Free-Survival-in-Metastatic-Colorectal-Cancer/default.aspxSun, 31 May 2026 08:00:00 -0400TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancerdbe2cdef-9685-47a6-989c-7dfdb91a2410https://investors.pfizer.com/Investors/news-events/News/news-details/2026/TALZENNA-Plus-XTANDI-Improves-Radiographic-Progression-Free-Survival-by-More-Than-50-in-Metastatic-Prostate-Cancer/default.aspxSat, 30 May 2026 08:00:00 -0400Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer18f2cd62-0423-4844-b02e-52caa164f6fdhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Seven-Year-Analysis-from-Pfizers-LORBRENA-CROWN-Trial-Shows-Longest-Progression-Free-Survival-Reported-to-Date-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxFri, 29 May 2026 08:00:00 -0400Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicinesa7248608-85bc-42f0-8b10-5a1f7e89fefahttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-and-Innovent-Biologics-Enter-Global-Strategic-Collaboration-to-Accelerate-Development-of-Innovative-Oncology-Medicines/default.aspxThu, 28 May 2026 19:00:00 -0400Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference593746eb-be21-4880-a137-11809387b043https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference-6fc99d217/default.aspxWed, 27 May 2026 10:00:00 -0400Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Resultsa5b6b84a-3c3b-4be0-8372-2b932e515eachttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Advances-Pivotal-Pediatric-Pneumococcal-Vaccine-Program-Following-Strong-Positive-Phase-2-Results/default.aspxWed, 20 May 2026 05:05:00 -0400European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors16b4ada8-3686-4117-ad58-bbd7c1544aadhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/European-Commission-Approves-Pfizers-HYMPAVZI-for-the-Treatment-of-Adults-and-Adolescents-with-Hemophilia-A-or-B-With-Inhibitors/default.aspxWed, 13 May 2026 06:45:00 -0400